Dexcom, Inc. has posted upbeat earnings for Q1 2026, with a reported growth of 15% and revenue hitting $1.19 billion. Despite facing a challenging market and accusations of misleading investors, the company has launched innovative products such as the Dexcom Flex in Germany. Currently priced at $71.88, Dexcom's stock reflects growing investor confidence, though a securities class action lawsuit looms due to alleged discrepancies in the company's sales strategies.
“Dexcom · has been developing · innovative technology · since 1999”
“Dexcom · offers · the best sensing solution · true”
“DexCom, Inc. · is a · medical device company · true”
“DexCom, Inc. · engages in the design, development, and commercialization of · glucose monitoring systems · true”
“DexCom · has products including · Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE · true”
“DexCom · was founded in · 1999 · true”
“DexCom · has headquarters in · San Diego, California · true”
“DexCom · has · 11,100 employees · true”
“DexCom(DXCM) stock · is priced at · $71.88 · true”
“DexCom(DXCM) stock · has a market capitalization of · $27.74B · true”
“DexCom(DXCM) stock · has a price-earnings ratio of · 30.55 · true”
“DexCom(DXCM) stock · has a 52-week high of · $89.98 · true”
.jpg&width=160)